Ethyl 1-(Bromomethyl)-4-methylenecyclohexanecarboxylate | 147151-52-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Ethyl 1-(Bromomethyl)-4-methylenecyclohexanecarboxylate
• 英文别名: ethyl 1-(bromomethyl)-4-methylidenecyclohexane-1-carboxylate
• CAS: 147151-52-8
• 化学式: C₁₁H₁₇BrO₂
• 分子量: 261.159
• InChiKey: MWSPMHIHMDBLGV-UHFFFAOYSA-N

物化性质

• 沸点：
  287.9±33.0 °C(Predicted)
• 密度：
  1.27±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  Ethyl 1-(Bromomethyl)-4-methylenecyclohexanecarboxylate 在 sodium tetrahydroborate 作用下， 以 六甲基磷酰三胺 为溶剂， 反应 2.0h， 以88%的产率得到Ethyl 1-methyl-4-methylenecyclohexanecarboxylate
  参考文献：
  名称：

  Synthesis of bridgehead-substituted bicyclo[2.2.1]heptanes by radical cyclization

  摘要：

  A kinetic investigation shows that the rate of cyclization (k(C)) of the (4-methylenecyclohexyl)methyl radical 3 at 25-degrees-C is 4.4 x 10(2) s-1, which is considerably slower than that (2.3 x 10(5) s-1) of the parent 5-hexenyl radical. The energy of activation for the process 3 - 4 is 12.8 kcal mol-1, which is in excellent agreement with theoretical values derived from force-field calculations. Ring-closure of appropriately substituted (4-methylenecyclohexyl)methyl radical precursors allows the synthesis of bicyclo[2.2.1]heptyl systems with useful functionality at the bridgehead to be achieved readily and in high yield. An interesting example is given of the application of an iodine-atom-transfer cyclization to the synthesis of a bicyclo[2.2.1]heptane functionalized at C7 and C1.

  DOI：

  10.1021/jo00060a029
• 作为产物：
  描述：

  4-羟基环己烷甲酸乙酯 在 sodium dichromate 、 硫酸 、 sodium hydride 、 lithium diisopropyl amide 作用下， 以 乙醚 、 水 为溶剂， 反应 7.42h， 生成 Ethyl 1-(Bromomethyl)-4-methylenecyclohexanecarboxylate
  参考文献：
  名称：

  Synthesis of bridgehead-substituted bicyclo[2.2.1]heptanes by radical cyclization

  摘要：

  A kinetic investigation shows that the rate of cyclization (k(C)) of the (4-methylenecyclohexyl)methyl radical 3 at 25-degrees-C is 4.4 x 10(2) s-1, which is considerably slower than that (2.3 x 10(5) s-1) of the parent 5-hexenyl radical. The energy of activation for the process 3 - 4 is 12.8 kcal mol-1, which is in excellent agreement with theoretical values derived from force-field calculations. Ring-closure of appropriately substituted (4-methylenecyclohexyl)methyl radical precursors allows the synthesis of bicyclo[2.2.1]heptyl systems with useful functionality at the bridgehead to be achieved readily and in high yield. An interesting example is given of the application of an iodine-atom-transfer cyclization to the synthesis of a bicyclo[2.2.1]heptane functionalized at C7 and C1.

  DOI：

  10.1021/jo00060a029

文献信息

• [EN] PYRAZOLE AMIDE DERIVATIVE<br/>[FR] DÉRIVÉ DE PYRAZOLE AMIDE
  申请人：TEIJIN PHARMA LTD

  公开号：WO2015129926A1

  公开（公告）日：2015-09-03

  The present invention relates to a novel compound having a function of inhibiting RORγ activity. The present invention also relates to pharmaceutical composition comprising the compound, a use of the compound in treating or preventing autoimmune diseases, inflammatory diseases, metabolic diseases, or cancer diseases.

  本发明涉及一种新型化合物，具有抑制RORγ活性的功能。本发明还涉及包括该化合物的药物组合物，以及在治疗或预防自身免疫疾病、炎症性疾病、代谢性疾病或癌症疾病中使用该化合物的用途。
• Pyrazole amide derivative
  申请人：AMGEN INC.

  公开号：US09365522B2

  公开（公告）日：2016-06-14

  The present invention relates to a novel compound having a function of inhibiting RORγ activity. The present invention also relates to pharmaceutical composition comprising the compound, a use of the compound in treating or preventing autoimmune diseases, inflammatory diseases, metabolic diseases, or cancer diseases.

  本发明涉及一种新型化合物，具有抑制RORγ活性的功能。本发明还涉及包含该化合物的药物组合物，以及使用该化合物治疗或预防自身免疫疾病、炎症性疾病、代谢性疾病或癌症疾病的用途。
• Pyrazole Amide Derivative
  申请人：AMGEN INC.

  公开号：US20150266824A1

  公开（公告）日：2015-09-24

  The present invention relates to a novel compound having a function of inhibiting RORγ activity. The present invention also relates to pharmaceutical composition comprising the compound, a use of the compound in treating or preventing autoimmune diseases, inflammatory diseases, metabolic diseases, or cancer diseases.

  本发明涉及一种新型化合物，具有抑制RORγ活性的功能。本发明还涉及包含该化合物的药物组合物，以及使用该化合物治疗或预防自身免疫性疾病、炎症性疾病、代谢性疾病或癌症疾病的用途。
• PYRAZOLE AMIDE DERIVATIVE
  申请人：Teijin Pharma Limited

  公开号：EP3110810A1

  公开（公告）日：2017-01-04
• US9365522B2
  申请人：——

  公开号：US9365522B2

  公开（公告）日：2016-06-14